Product category:
Contract research
News Release from: Maybridge
Edited by the Laboratorytalk Editorial
Team on 03 September 2002
Proprietary library synthesis
collaboration
Pharmaceutical leader turns to compound producer to assist in development of new screening library
Maybridge, a producer and supplier of organic compounds for drug discovery and development in the pharmaceutical, biotechnology and agrochemical industries, and Roche, one of the world's leading research-oriented healthcare groups, have announced ythat the two companies will collaborate on the creation of a proprietary screening library, based on Maybridge's novel collection of Reactive Intermediates Once completed, the new library will be owned and maintained exclusively by Roche
This article was originally published on Laboratorytalk on 10 Dec 2002 at 8.00am (UK)
Related stories
Compounds assist malaria drug development
MRC researchers achieve a significant hit-rate when using screening compounds in a novel high throughput screening (HTS) assay designed to identify potential anti-malaria agents
The detailed collaboration will entail Maybridge and Roche scientists working closely to develop the new library, as both companies bring key elements to the table.
Maybridge, known for its skills in heterocyclic organic chemistry, offers one of the best commercially available monomer libraries of diverse reactive intermediates for hit-to-lead optimization.
Roche will apply its proprietary approach to their library design as well as over 100 years of industry experience.
"Maybridge is pleased to have this opportunity to work with a well-respected and leading pharmaceutical company, like Roche," said Nick Kerton, chief executive officer.
"Roche's desire to add proprietary and unique library compounds by leveraging.
• Maybridge: contact details and other news
• Email this article to a colleague
• Register for the free Laboratorytalk email newsletter
• Laboratorytalk Home Page
Search the Pro-Talk network of sites
